论文部分内容阅读
肿瘤相关巨噬细胞(TAM)来源于血液中的巨噬细胞,进入肿瘤组织后,在细胞因子的刺激下可极化为“M1”型或“M2”型TAM。“M1”型TAM抑制肿瘤生长,“M2”型TAM通过产生各种促进肿瘤生长因子影响肿瘤发生发展过程,如:血管生成、免疫抑制、侵袭和转移。越来越多的研究表明,肿瘤相关巨噬细胞可增强或拮抗化学药物治疗、放射治疗和免疫治疗剂的抗肿瘤治疗疗效,也能带动肿瘤在放射治疗或血管靶向药物治疗之后的修复机制。因此,研究临床抗肿瘤治疗过程,TAM参与肿瘤免疫治疗的机制可为肿瘤免疫治疗提供新靶点。本文主要讨论TAM调节抗肿瘤治疗研究进展。
Tumor-associated macrophages (TAMs) are derived from macrophages in the blood and enter the tumor tissue and are polarized to “M1” or “M2” TAMs, stimulated by cytokines. “M1” type TAM inhibits tumor growth, and “M2” type TAM affects tumorigenesis and development by generating various promoters of tumor growth factors such as angiogenesis, immunosuppression, invasion and metastasis. More and more studies have shown that tumor-associated macrophages can enhance or antagonize the anti-tumor efficacy of chemotherapeutic, radiotherapy and immunotherapeutic agents and can also promote the repair mechanism of tumors after radiation therapy or vascular-targeted drug treatment . Therefore, the study of clinical anti-tumor treatment process, TAM mechanisms involved in tumor immunotherapy can provide a new target for tumor immunotherapy. This article focuses on TAM regulatory antitumor therapy research progress.